Pharmacy sales in Ukraine for the January–September 2026 period rose by 16.7% in monetary terms compared to the same period in 2025—reaching nearly 186.387 billion UAH, while in volume terms, they fell by 5%, to nearly 802.242 million packages, the company “Business Credit” reported to the Interfax-Ukraine news agency, citing a study it conducted.
According to the report, the weighted average price of the pharmacy basket for the period in question was 232.33 UAH per package, which is 22.91% higher than during the same period a year earlier.
At the same time, pharmacy sales of medicines increased by 23.12% in monetary terms—to more than 152.26 billion UAH—and by 6.34% in volume terms—to nearly 634.961 million packages.
The weighted average retail price of pharmaceuticals for the first nine months of 2026 was 239.79 UAH per package, which is 15.79% higher than in January–September 2025.
At the same time, pharmacy sales of dietary supplements in the first nine months of 2026 increased by 7.5% in monetary terms—to nearly 19.764 billion UAH—while in volume terms they decreased by 17.7%—to 59.913 million packages. The weighted average price in this segment rose by 30.72%—to 329.88 UAH per unit.
Business Credit notes that from January through September 2026, the highest price increases in pharmacy retail were seen in products for parenteral administration of medications (syringes, injection needles, infusion sets/drip sets/transfusion sets, catheters—IF-U), which rose in price by 53.47%.
Overall, according to the company’s data, in the pharmacy retail sector over the first nine months of 2026, sales volumes in monetary terms decreased across all product categories except dietary supplements (+7.5%), therapeutic cosmetics (+21.4%), and mineral water (+4.8%).
At the same time, in volume terms, pharmacy sales increased only in the pharmaceuticals category.
As previously reported, pharmacy sales in Ukraine for the period from January through August 2026 increased by 15.7% in monetary terms compared to the same period in 2025—to more than nearly 162 billion UAH—while in volume terms, they decreased by 5.86%, to nearly 707,313 thousand packages. The weighted average price of items in the pharmacy basket for the period was 229.76 UAH per package, which is 22.88% higher than during the same period a year earlier.
At the same time, pharmacy sales of pharmaceuticals increased by 21.32% in monetary terms—to nearly 132.199 billion UAH—and by 5.13% in volume terms—to nearly 556.962 million packages. The weighted average retail price of medicines for the first eight months of 2026 was 237.36 UAH per package, which is 15% higher than in January–August 2025.
For the full year 2025, pharmacy sales in monetary terms increased by 14.23% compared to 2024—to more than 220.287 billion UAH—while in volume terms, they decreased by 2.25%, to nearly 1.135 million packages. The weighted average price of items in the pharmacy basket was 194.68 UAH per package, which is 16.86% higher than a year earlier. Pharmacy sales of medicines in 2025 increased by 12.79% in monetary terms—to nearly 170.318 billion UAH—while in volume terms, they decreased by 0.2% compared to 2024, to 808.546 million packages. The weighted average retail price of pharmaceuticals at the end of 2025 was 210.65 UAH per package, which is 13% higher than at the end of 2024.
Poltava Medical Glass Plant JSC (PMGP, Poltava) saw its net profit decline by 15.8% in January–September 2026 compared to the same period in 2025, down to 66.05 million UAH.
According to the company’s interim report filed with the National Securities and Stock Market Commission’s disclosure system, its net sales revenue rose by 25.3% to 329.2 million UAH.
In January–September, the plant generated UAH 72.9 million in operating profit (down 14%), while gross profit increased slightly to UAH 107.5 million.
During this period, the plant manufactured 263 million ampoules and shipped 432.5 million units worth UAH 311 million.
The company generated 17.3 million UAH from the sale of oxygen and nitrogen.
As previously reported, in 2025, PZMS saw its net profit decline by 19% compared to 2024—to 105.564 million UAH—due to a 3.5% decrease in net revenue, which fell to 364.281 million UAH.
According to data from the National Securities and Stock Market Commission as of August 2026, 59.7% of the company’s authorized capital is owned by Supervisory Board Chairman Leonid Nekrasov, nearly 10% by Management Board Chairman Oleksandr Kudatsky, and another 25% is held by the pharmaceutical manufacturer PJSC “Ukrmedprom” (Kyiv), which falls under the jurisdiction of the Ministry of Health of Ukraine.
According to information on its website, the Poltava Medical Glass Plant is Ukraine’s leading manufacturer of ampoules for pharmaceuticals.
ampoule, PHARMACEUTICALS, Poltava Medical Glass Plant, PRODUCTION, PROFIT
When importing medicines in foreign packaging that were manufactured for the markets of other countries, the distribution of these imported medicines is carried out in accordance with general rules.
As the Ukrainian Agency for Medicines notes, the possibility of importing medicines in foreign packaging is permitted for the entire duration of martial law and for 6 months following its termination. This provision is intended to ensure the supply of medicines to all healthcare facilities, including hospitals and pharmacies.
“The law does not require any additional notifications or special confirmations that a batch is being imported for a specific healthcare facility; the distribution of such medicines is carried out in accordance with general regulations,” the Ukrainian State Agency for Medicines clarifies.
At the same time, the agency notes that a drug in foreign packaging must be completely identical to the one registered in Ukraine—that is, it must match 100% in terms of the qualitative and quantitative composition of active and excipients, packaging, and must have the same approved manufacturing sites, specifications, quality control methods, and expiration dates, among other things.
However, differences in the labeling and design of the packaging itself are permitted.
Each package must be accompanied by a package insert approved in Ukraine.
“The responsibility to provide this accompanying documentation rests with the importer,” emphasizes the Ukrainian Agency for Medicines.
IMPORT, MARTIAL LAW, MEDICINES, PHARMACEUTICALS, Ukrainian Agency for Medicines
The “Podorozhnik” pharmacy chain (Lviv) has topped the ranking of the country’s pharmacy chains by number of locations and sales.
According to the publication “Apteka,” second in the ranking of the largest chains by number of locations is the “Apteka 9-1-1” chain (Kharkiv), which operates under the “9-1-1” and “Apteka Wholesale Prices” brands; in third place is “Apteka-Magnolia” LLC (Zaporizhzhia), known for the brands ANC, “Kopiyka,” “Shara,” and “Blagodiya”; in fourth place is “Sirius-95” LLC (Kyiv), which operates under the “We Wish You Health” brand; in fifth place is “Pharmastor” LLC (Kyiv, “Good Day Pharmacy”).
In terms of sales volume, “Apteka-Magnolia” ranks second in the top 5, third place goes to the “Apteka 9-1-1” chain, and fourth and fifth places are held by “Sirius-95” and “Farmastor” (“Bazhaemo Zdorov’ya” and “Apteka Dobrogo Dnya”).
The publication does not report the number of retail locations, but media outlets cite varying numbers depending on the calculation method.
As the “Podorozhnik” chain clarified to the Interfax-Ukraine news agency, as of the end of August 2026, this pharmacy chain’s turnover reached 3.814 billion UAH, with approximately 2,400 retail locations.
As a result of an enemy attack, the Kusum pharmaceutical plant in Sumy was destroyed, and one employee was killed.
“This morning, the production facility of the Kusum pharmaceutical company in Sumy was destroyed as a result of an enemy attack. Unfortunately, the attack claimed the life of company employee Yevgeny Vladimirovich Miroshnichenko, who had worked in the plant’s engineering department since 2009. ‘Kusum’ extends its sincere condolences to his family and loved ones,” the company stated on its website.
The company reports that ‘Kusum’ continues to operate.
” In addition to its production facilities in Ukraine, the company has manufacturing sites in India—in Indore and Bhiwadi. “This will allow us, in the absence of artificial regulatory barriers, to restructure our processes and work to ensure uninterrupted supplies of medicines to Ukraine,” the pharmaceutical company stated.
The biopharmaceutical company Biopharma Plasma (Kyiv) has opened a plasma center in Kolomyia (Ivano-Frankivsk Oblast), marking the company’s 23rd plasma center. The company announced this on LinkedIn.
“This new center is another step toward expanding access to plasma donation and strengthening our contribution to the production of life-saving medicines,” the company stated.
As previously reported, in June, Biopharma Plasma opened a plasma center in Zhytomyr, which became the company’s 22nd plasma center. Before the war, Biopharma Plasma planned to open approximately four to five new centers each year, investing about $2.5 million in each.
By the end of 2027, Biopharma plans to launch a plant in Oradea, Romania, with an initial investment of 85 million euros. In September of this year, the company plans to launch the first phase of its plant in Uzhhorod for the production of pharmaceutical products and immunobiological preparations, which will provide a full cycle of blood plasma processing. The company has already invested 67 million euros in the construction; the total cost of the first phase is 75 million euros. According to the plan, the volume of blood plasma-based drug production in Uzhhorod will be twice that of production in Bila Tserkva, amounting to up to 1.5 million liters of blood plasma per year, while the project in Romania will be twice as large.
Biopharma Plasma, Donation, Kolomyia, PHARMACEUTICALS, PLASMA
